Safe like mRNA
No capsid, no anti-AAV immunity, and no genome cutting. Non-integrating by design — a cleaner safety story than CRISPR or lentivirus.
A new class of gene therapy
Nyxa makes durable gene therapies — delivered like a vaccine, programmed like software, without viruses.
The idea
Today, gene therapy delivers DNA. We deliver the recipe to make DNA — inside the cell. It is all RNA, manufactured the same way as a COVID vaccine.
We send the cell RNA instructions — the same kind of molecule as an mRNA vaccine.
A tiny lipid droplet carries them into the cell. A simple, re-doseable shot.
The cell reads the instructions and makes its own lasting copy of the healthy gene.
That copy keeps making the needed protein long-term — and can be topped up.
Delivered like a vaccine — lasts like a gene therapy.
Differentiation
No capsid, no anti-AAV immunity, and no genome cutting. Non-integrating by design — a cleaner safety story than CRISPR or lentivirus.
The written copy keeps expressing long-term — and a self-renewing version duplicates each cell division, holding up even in growing pediatric tissue where AAV fades.
Swap the template, change the gene. One RNA process, vaccine-like economics — potentially far lower cost-of-goods than AAV.
Get in touch
We’re building the delivery platform that comes after AAV. If you invest in, partner with, or want to build genome medicine, let’s talk.
contact@nyxatx.com